CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?
We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...
CervoMed price target raised to $20 from $15 at Roth MKM
Roth MKM raised the firm’s price target on CervoMed (CRVO) to $20 from $15 and keeps a Buy rating on the shares. The firm is positive on the ...
CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now
We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...
CervoMed Shares Rise After Positive Data From Neflamapimod Trial
The clinical-stage company on Monday said that, following "highly encouraging" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a ...
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), ...
Why CervoMed Inc. (CRVO) Soared Last Week?
We recently published a list of These 10 Stocks Posted Double-, Triple-Digit Gains Last Week. In this article, we are going ...